Resona Asset Management Co. Ltd. Trims Stake in Cencora, Inc. $COR

Resona Asset Management Co. Ltd. lessened its holdings in Cencora, Inc. (NYSE:COR) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,721 shares of the company’s stock after selling 1,761 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Cencora were worth $29,870,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the business. Acadian Asset Management LLC boosted its position in Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after acquiring an additional 232,539 shares during the last quarter. Segment Wealth Management LLC purchased a new position in Cencora in the 3rd quarter worth approximately $4,830,000. Exchange Traded Concepts LLC lifted its stake in Cencora by 312.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 10,458 shares of the company’s stock worth $3,268,000 after purchasing an additional 7,924 shares in the last quarter. Synergy Asset Management LLC acquired a new position in shares of Cencora during the 3rd quarter worth approximately $10,093,000. Finally, Kathmere Capital Management LLC increased its holdings in shares of Cencora by 42.3% in the second quarter. Kathmere Capital Management LLC now owns 3,265 shares of the company’s stock valued at $979,000 after purchasing an additional 970 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 20,316 shares of company stock valued at $7,151,265. 10.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on COR shares. Mizuho boosted their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday. Bank of America reduced their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Wells Fargo & Company increased their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, Barclays started coverage on shares of Cencora in a research report on Monday, December 8th. They set an “overweight” rating and a $400.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $393.08.

Cencora Stock Up 0.2%

Shares of NYSE COR opened at $353.07 on Friday. Cencora, Inc. has a 52-week low of $237.71 and a 52-week high of $377.54. The business’s 50 day moving average is $348.49 and its two-hundred day moving average is $322.06. The firm has a market cap of $68.49 billion, a price-to-earnings ratio of 44.41, a PEG ratio of 1.68 and a beta of 0.66. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.